Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 1/2019

Open Access 01-02-2019 | Hepatic Encephalopathy | Review Article

l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses

Authors: Roger F. Butterworth, Mark J. W. McPhail

Published in: Drugs | Special Issue 1/2019

Login to get access

Abstract

This manuscript represents an appraisal of the evidence in support of l-ornithine-l-aspartate (LOLA) for the management and treatment of hepatic encephalopathy (HE) in cirrhosis. Meta-analyses of randomized controlled trials (RCTs) conducted over the last two decades generally reveal evidence of benefit of LOLA in a range of clinical presentations. This included improvement of mental state grade in overt HE (OHE) assessed by West Haven criteria as well as in minimal HE (MHE) assessed by psychometric testing where the oral formulation of LOLA was determined to be particularly effective. However, concerns over study quality were noted in one meta-analysis. Nevertheless, the concomitant lowering of fasting blood ammonia was reported in all RCTs using this endpoint. Network meta-analyses showed that LOLA appears to be comparable (or superior) in efficacy to non-absorbable disaccharides or probiotics. Emerging evidence from single RCTs show efficacy of LOLA for the treatment of post-transjugular intrahepatic portosystemic shunt (TIPSS) HE as well as for secondary HE prophylaxis. These findings provide support for the use of LOLA in the treatment of HE and future trials should focus on the use of LOLA for prophylaxis.
Literature
1.
Delcker AM, Jalan R, Schumacher M, Comes G. l-Ornithine l-aspartate versus placebo in the treatment of hepatic encephalopathy: a meta-analysis of randomised placebo-controlled trials using individual data. Hepatology. 2000;4:604 (abstract).
2.
Jiang Q, Jiang XH, Zheng MH, Chen YP. l-Ornithine l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol. 2009;24:9–14.CrossRefPubMed
3.
Bai M, Yang Z, Qi X, Fan D, Han G. l-Ornithine l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2013;28:783–92.CrossRefPubMed
4.
Goh ET, Stokes CS, Vilstrup H, Gluud LL, Morgan MY. l-Ornithine l-aspartate for hepatic encephalopathy: a systematic review with meta-analysis of randomised controlled trials. J Hepatol. 2017;66:131 (abstract).CrossRef
5.
6.
7.
8.
Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Goertelmeyer R, et al. Therapeutic efficacy of l-ornithine–l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25:1351–60.CrossRefPubMed
9.
Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Goertelmeyer R, et al. Oral l-ornithine–l-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998;28:856–64.CrossRefPubMed
10.
Chen M, Li R, Chen C, Gao X. Observation of clinical effect of l-ornithine l-aspartate therapy on liver cirrhosis complicated by hepatic encephalopathy. Chin Libr Class. 2005;2588:06-0718-02.
11.
Schmid M, Peck-Radosavljevic M, König F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. Liver Int. 2010;30:574–82.CrossRefPubMed
12.
Abid S, Jafri W, Mumtaz K, Islam M, Abbas Z, Shah HA, et al. Efficacy of l-ornithine–l-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J Coll Phys Surg Pak. 2011;21:666–71.
13.
Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, l-ornithine l-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2011;23(8):725–32.CrossRefPubMed
14.
Alvares da Silva MR, de Araujo A, Vicenzi JR, da Silva GV, Oliveira FB, Schacher F, et al. Oral l-ornithine–l-aspartate in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:956–63.CrossRefPubMed
15.
Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. l-Ornithine l-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67:700–10.CrossRefPubMed
16.
Ahmad I, Khan AA, Alam A, Dilshad A, Butt AK, Shafqat F, et al. l-Ornithine–l-aspartate infusion efficacy in hepatic encephalopathy. J Coll Phys Surg Pak. 2008;18:684–7.
17.
Sharma K, Pant S, Misra S, Dwivendi M, Misra A, Narang S, et al. Effect of rifaximin, probiotics and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014;20:225–32.CrossRefPubMedPubMedCentral
18.
Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M, et al. Efficacy of oral l-ornithine l-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006;5:281–8.CrossRef
19.
Zhu GQ, Shi KQ, Huang S, Wang LR, Lin YQ, Huang GQ, et al. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther. 2015;41:624–35.CrossRefPubMed
20.
21.
Roessle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Eng J Med. 1994;330:165–71.CrossRef
22.
Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674–9.CrossRefPubMed
23.
Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of l-ornithine–l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut. 2000;47:571–4.CrossRefPubMedPubMedCentral
24.
Bai M, He C, Yin Z, Niu J, Wang Z, Qi X, et al. Randomised clinical trial: l-ornithine–l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther. 2014;40:63–71.CrossRefPubMed
25.
Butterworth RF, Gruengreiff K. l-Ornithine l-aspartate (LOLA) for the treatment of hepatic encephalopathy in cirrhosis: evidence for novel hepatoprotective mechanisms. J Liver Clin Res. 2018;5:1044.
26.
27.
Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332–40.CrossRefPubMedPubMedCentral
28.
Sotil EU, Gottstein J, Ayala E, Randolph C, Blei AT. Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl. 2009;15:184–92.CrossRefPubMed
29.
Amodio P. Solving doubts about l-ornithine l-aspartate for overt hepatic encephalopathy: whom and how to treat. Hepatology. 2018;67:476–8.CrossRefPubMed
Metadata
Title
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses
Authors
Roger F. Butterworth
Mark J. W. McPhail
Publication date
01-02-2019
Publisher
Springer International Publishing
Published in
Drugs / Issue Special Issue 1/2019
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-018-1024-1

Other articles of this Special Issue 1/2019

Drugs 1/2019 Go to the issue

Research Article

l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease

Review Article

Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues

Review Article

Pharmacokinetic and Pharmacodynamic Properties of l-Ornithine l-Aspartate (LOLA) in Hepatic Encephalopathy

Review Article

Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles

Editorial

l-Ornithine l-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic

Review Article

Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology